

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following bispecific antibodies is FDA approved for the management of relapsed/refractory (R/R) follicular lymphoma (FL)?
 - Epcoritamab
 - Glofitamab
 - Mosunetuzumab
 - Odronex-tamab
 - All of the above
- What was the approximate overall response rate reported with odronex-tamab for patients with R/R FL in the ELM-2 trial?
 - 33%
 - 46%
 - 60%
 - 81%
- The FDA has launched an investigation into the risk of which of the following adverse events for patients receiving CAR (chimeric antigen receptor) T-cell therapies?
 - Cardiac toxicities
 - Neurologic and psychiatric events
 - Acute kidney injury
 - T-cell cancers
- What was the approximate overall response rate observed with pirtobrutinib for patients who previously received another Bruton tyrosine kinase inhibitor for mantle cell lymphoma in the Phase I/II BRUIN study?
 - Approximately 25%
 - Approximately 40%
 - Approximately 55%
- Approximately what proportion of patients with high-risk large B-cell lymphoma experienced a response to first-line axicabtagene ciloleucel in the Phase II ZUMA-12 trial?
 - 20%
 - 50%
 - 85%